Literature DB >> 34252381

Difference in mortality among individuals admitted to hospital with COVID-19 during the first and second waves in South Africa: a cohort study.

Waasila Jassat1, Caroline Mudara2, Lovelyn Ozougwu2, Stefano Tempia3, Lucille Blumberg2, Mary-Ann Davies4, Yogan Pillay5, Terence Carter5, Ramphelane Morewane6, Milani Wolmarans6, Anne von Gottberg7, Jinal N Bhiman7, Sibongile Walaza2, Cheryl Cohen3.   

Abstract

BACKGROUND: The first wave of COVID-19 in South Africa peaked in July, 2020, and a larger second wave peaked in January, 2021, in which the SARS-CoV-2 501Y.V2 (Beta) lineage predominated. We aimed to compare in-hospital mortality and other patient characteristics between the first and second waves.
METHODS: In this prospective cohort study, we analysed data from the DATCOV national active surveillance system for COVID-19 admissions to hospital from March 5, 2020, to March 27, 2021. The system contained data from all hospitals in South Africa that have admitted a patient with COVID-19. We used incidence risk for admission to hospital and determined cutoff dates to define five wave periods: pre-wave 1, wave 1, post-wave 1, wave 2, and post-wave 2. We compared the characteristics of patients with COVID-19 who were admitted to hospital in wave 1 and wave 2, and risk factors for in-hospital mortality accounting for wave period using random-effect multivariable logistic regression.
FINDINGS: Peak rates of COVID-19 cases, admissions, and in-hospital deaths in the second wave exceeded rates in the first wave: COVID-19 cases, 240·4 cases per 100 000 people vs 136·0 cases per 100 000 people; admissions, 27·9 admissions per 100 000 people vs 16·1 admissions per 100 000 people; deaths, 8·3 deaths per 100 000 people vs 3·6 deaths per 100 000 people. The weekly average growth rate in hospital admissions was 20% in wave 1 and 43% in wave 2 (ratio of growth rate in wave 2 compared with wave 1 was 1·19, 95% CI 1·18-1·20). Compared with the first wave, individuals admitted to hospital in the second wave were more likely to be age 40-64 years (adjusted odds ratio [aOR] 1·22, 95% CI 1·14-1·31), and older than 65 years (aOR 1·38, 1·25-1·52), compared with younger than 40 years; of Mixed race (aOR 1·21, 1·06-1·38) compared with White race; and admitted in the public sector (aOR 1·65, 1·41-1·92); and less likely to be Black (aOR 0·53, 0·47-0·60) and Indian (aOR 0·77, 0·66-0·91), compared with White; and have a comorbid condition (aOR 0·60, 0·55-0·67). For multivariable analysis, after adjusting for weekly COVID-19 hospital admissions, there was a 31% increased risk of in-hospital mortality in the second wave (aOR 1·31, 95% CI 1·28-1·35). In-hospital case-fatality risk increased from 17·7% in weeks of low admission (<3500 admissions) to 26·9% in weeks of very high admission (>8000 admissions; aOR 1·24, 1·17-1·32).
INTERPRETATION: In South Africa, the second wave was associated with higher incidence of COVID-19, more rapid increase in admissions to hospital, and increased in-hospital mortality. Although some of the increased mortality can be explained by admissions in the second wave being more likely in older individuals, in the public sector, and by the increased health system pressure, a residual increase in mortality of patients admitted to hospital could be related to the new Beta lineage. FUNDING: DATCOV as a national surveillance system is funded by the National Institute for Communicable Diseases and the South African National Government.
Copyright © 2021 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4.0 license. Published by Elsevier Ltd.. All rights reserved.

Entities:  

Year:  2021        PMID: 34252381     DOI: 10.1016/S2214-109X(21)00289-8

Source DB:  PubMed          Journal:  Lancet Glob Health        ISSN: 2214-109X            Impact factor:   26.763


  56 in total

1.  Remember Beta? New data reveal variant's deadly toll.

Authors:  Ewen Callaway
Journal:  Nature       Date:  2021-08-09       Impact factor: 49.962

2.  Comparison of the clinical presentation across two waves of COVID-19: a retrospective cohort study.

Authors:  Henriette Nørmølle Buttenschøn; Vibeke Lynggaard; Susanne Gundersborg Sandbøl; Eva Natalia Glassou; Annette Haagerup
Journal:  BMC Infect Dis       Date:  2022-05-03       Impact factor: 3.667

3.  Prognostic value of biochemical parameters among severe COVID-19 patients admitted to an intensive care unit of a tertiary hospital in South Africa.

Authors:  Annalise E Zemlin; Brian Allwood; Rajiv T Erasmus; Tandi E Matsha; Zivanai C Chapanduka; Thumeka P Jalavu; Vera Ngah; Lovemore N Sigwadhi; Coenraad F Koegelenberg; Elvis Irusen; Usha Lalla; Anteneh Yalew; Nicola Baines; Jacques L Tamuzi; Anne K Barasa; Valerie Kemunto Magutu; Caroline Njeru; Angela Amayo; Marianne Wanjiru Mureithi; Mary Mungania; Musa Sono-Setati; Alimuddin Zumla; Peter S Nyasulu
Journal:  IJID Reg       Date:  2022-01-23

Review 4.  SARS-CoV-2: Evolution and Emergence of New Viral Variants.

Authors:  Verónica Roxana Flores-Vega; Jessica Viridiana Monroy-Molina; Luis Enrique Jiménez-Hernández; Alfredo G Torres; José Ignacio Santos-Preciado; Roberto Rosales-Reyes
Journal:  Viruses       Date:  2022-03-22       Impact factor: 5.818

5.  Clinical management of COVID-19 in hospitals and the community: A snapshot from a medical insurance database in South Africa.

Authors:  S Mametja; Zelalem G Dessie; L Matoti; M Semenya; S Moloabi; S Y Essack
Journal:  Int J Infect Dis       Date:  2022-04-22       Impact factor: 12.074

6.  Imported SARS-COV-2 Variants of Concern Drove Spread of Infections Across Kenya During the Second Year of the Pandemic.

Authors:  Carolyne Nasimiyu; Damaris Matoke-Muhia; Gilbert K Rono; Eric Osoro; Daniel O Obado; J Milkah Mwangi; Nicholas Mwikwabe; Kelvin Thiongâ O; Jeanette Dawa; Isaac Ngere; John Gachohi; Samuel Kariuki; Evans Amukoye; Marianne Mureithi; Philip Ngere; Patrick Amoth; Ian Were; Lyndah Makayotto; Vishvanath Nene; Edward O Abworo; M Kariuki Njenga; Stephanie N Seifert; Samuel O Oyola
Journal:  medRxiv       Date:  2022-02-28

7.  Assessing the potential impact of immunity waning on the dynamics of COVID-19 in South Africa: an endemic model of COVID-19.

Authors:  Musa Rabiu; Sarafa A Iyaniwura
Journal:  Nonlinear Dyn       Date:  2022-01-25       Impact factor: 5.741

8.  High Mortality During the Second Wave of the Coronavirus Disease 2019 (COVID-19) Pandemic in Uganda: Experience From a National Referral COVID-19 Treatment Unit.

Authors:  Felix Bongomin; Brian Fleischer; Ronald Olum; Barbra Natukunda; Sarah Kiguli; Pauline Byakika-Kibwika; Joseph Baruch Baluku; Frederick Nelson Nakwagala
Journal:  Open Forum Infect Dis       Date:  2021-11-18       Impact factor: 3.835

9.  Outcomes of laboratory-confirmed SARS-CoV-2 infection in the Omicron-driven fourth wave compared with previous waves in the Western Cape Province, South Africa.

Authors:  Mary-Ann Davies; Reshma Kassanjee; Petro Rosseau; Erna Morden; Leigh Johnson; Wesley Solomon; Nei-Yuan Hsiao; Hannah Hussey; Graeme Meintjes; Masudah Paleker; Theuns Jacobs; Peter Raubenheimer; Alexa Heekes; Pierre Dane; Jamy-Lee Bam; Mariette Smith; Wolfgang Preiser; David Pienaar; Marc Mendelson; Jonathan Naude; Neshaad Schrueder; Ayanda Mnguni; Sue Le Roux; Katie Murie; Hans Prozesky; Hassan Mahomed; Liezel Rossouw; Sean Wasserman; Deborah Maughan; Linda Boloko; Barry Smith; Jantjie Taljaard; Greg Symons; Ntobeko Ntusi; Arifa Parker; Nicole Wolter; Waasila Jassat; Cheryl Cohen; Richard Lessells; Robert J Wilkinson; Juanita Arendse; Saadiq Kariem; Melvin Moodley; Krish Vallabhjee; Milani Wolmarans; Keith Cloete; Andrew Boulle
Journal:  medRxiv       Date:  2022-01-12

10.  HIV status alters disease severity and immune cell responses in Beta variant SARS-CoV-2 infection wave.

Authors:  Farina Karim; Inbal Gazy; Sandile Cele; Yenzekile Zungu; Robert Krause; Mallory Bernstein; Khadija Khan; Yashica Ganga; Hylton Rodel; Ntombifuthi Mthabela; Matilda Mazibuko; Daniel Muema; Dirhona Ramjit; Thumbi Ndung'u; Willem Hanekom; Bernadett Gosnell; Richard J Lessells; Emily B Wong; Tulio de Oliveira; Mahomed-Yunus S Moosa; Gil Lustig; Alasdair Leslie; Henrik Kløverpris; Alex Sigal
Journal:  Elife       Date:  2021-10-05       Impact factor: 8.140

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.